untitled
|
|
|
- ゆたか ひがき
- 7 years ago
- Views:
Transcription
1 6 ( ) ( )
2 . 1. 1) 1 (12 3 ) 2
3 2) 3) ( ) ( ) 4) 2 () ) ( )
4 R-Book ATLAS () ( ) RS ( 18 ) ( SARS )( A A H5N1 ) ((H5N1) ( ) ( ) () ()
5 5 2 (H5N1) ( ) (3 )
6 . 1. 1) IgG IgM 2) 95% () (10 21 ) () ) () ( 5 7 ) 4) 2 () (1) 1 2 ( 5 7 ) ID
7 3ml ( ) (2) 3 (72 ) 6 (100mg/kg 1 ) () () (20mg/kg 4 5 ) (3) () (( ) (3 ) (9 ) (7 5 )
8 2. 1) 2 3 IgM RT-PCR (RNA) IgG Secondary vaccine failure( ) ) 95% () ( 2 ) 4 ( ) 1 () ) () 7
9 4) 2 () (1) ID 3ml ( ) (2) 72 6 () () (20mg/kg ) (3) () ( ) (3 ) (6 )
10 3. 1) () ( HI ) 25 40% (12 ) 3 10% 14 18% ( 4 ) 20% ) () 5 4) 2 () (1) ID
11 3ml ( ) (2) 5) () ( )
12 4. 1) 25% 10 15% ( ) IgM 2 IgG 4 2) () 7 9 -( 20 30% ) ( 5% ) (3 10%)(1/5 000 )(1/400 )( 30% ) 30 40% (2 ) 5 7 EIA-IgM 3) () 9 4) 2 () (1)
13 7 ID 3ml ( ) (2) 72 2 (1/12 000) (1/100 ) ( ) 5) ( ) () ( )
14 5. ( ) 1) B19 (slapped-cheek) () B19 (IgM IgG ) B19 DNA PCR( ) 2) % 30 40% 1 ( ) 3) 4) 2 () 1 (Aplastic crisis) Aplastic crisis α % 5)
15 6. 1) A B 2) ( 38) ( 2 ) ( ) ) ( ) ( ) ( ) ( ) ( 48 ) (48 )
16 R R R R R A A &B A &B A &B A &B ) (1) 1 (2) (3 ) (3) (12 3 )
17 2 (4) (5) (6) (7) ( ) WEB 2013/02/27
18 (:3064 :5888) 5) ( ) (3 ) ( 3 ) 6) 2 () (1) 1 ( ) 1 ( )
19 R 75(1 1 7 ) R ( ) R 75 R 37.5kg R R 3%1 2mg/kg( 66.7mg/kg) mg R ) 2
20 7. 1) RT-PCR PCR EIA 70% ( ) 2) 1 2 ( ) (SRSV) )
21 0.02% 0.05% 10 ( N95 ) 0.1% ( 2 )0.1% % ) (1) () () 1 (2) () (2 ) () (3) () ()
22 () (4) () (5) () (6) () 5) 0.02% 0.05% 0.02% 0.05%
23 ( N95 ) 0.1% 2 0.1% () 0.1% ( ) ( 2 )0.1% % 0.05% 0.02% 0.05%
24 6) 2 () 3 3 7) 1 4 8)
25 8. (epidemic keratoconjunctivitis EKC) 1) A F G A G D QOL 70% 2) ( ) 7 () 10 2 () () 70 A ) (1) () 80% 80%
26 (2) () (3) () 80% EKC () ( )( ) 0.1% % w/v%( ) 10 ()
27 4) 2 () )
23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
表1_表4
HN- 95 HN- 93 HN- 90 HN- 87 HN- 85 HN- 82 HN- 80 HN- 77 HN- 75 HN- 72 HN- 70 HN- 67 HN- 65 HN- 60 HN- 55 HN- 50 HN- 45 HN- 40 HN- 35 HN- 30 HN- 25 HN- 20 HN- 15 HN- 10 H02-80H H02-80L H02-70T H02-60H H05-60F
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
- 1 - A B C D E or or D or or d - 2 - A p18 P19 P21-3 - - 4 - B 2001 P21 P18 P19-5 - - 6 - C P21-7 - - 8 - D P21-9 - P16-10 - E - 11 - RT-PCR - 12 - P16-13 - P21-14 - P16-15 - - 16 - - 17 - Yes No Yes
23 3 11 24 21 24 25 4 28 4 2 7 161 2,692 28 12 14 18 18 380 5 3 1 27 21 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213 640 416 82,979
P-12 P-13 3 4 28 16 00 17 30 P-14 P-15 P-16 4 14 29 17 00 18 30 P-17 P-18 P-19 P-20 P-21 P-22
1 14 28 16 00 17 30 P-1 P-2 P-3 P-4 P-5 2 24 29 17 00 18 30 P-6 P-7 P-8 P-9 P-10 P-11 P-12 P-13 3 4 28 16 00 17 30 P-14 P-15 P-16 4 14 29 17 00 18 30 P-17 P-18 P-19 P-20 P-21 P-22 5 24 28 16 00 17 30 P-23
untitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
untitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
- 1 - - 0.5%5 10 10 5 10 1 5 1
- - - 1 - - 0.5%5 10 10 5 10 1 5 1 - 2 - - - - A B A A A B A B B A - 3 - - 100 100 100 - A) ( ) B) A) A B A B 110 A B 13 - 4 - A) 36 - - - 5 - - 1 - 6-1 - 7 - - 8 - Q.15 0% 10% 20% 30% 40% 50% 60% 70%
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
23 3 11 21 24 28 4 31,371 20,822 34,511 21,720 12,278 9,574 7,502 137,778 1 69 83.49% 70 15.55% 0.96 3.61% 40 1.19% 1055 29.65% 28 10 1 2 230,250 43,150 656 138,000 137,832 137,820 121,000 30,000 246,800
16 41 17 22 12 10
1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6
製品案内 価格表 2014/4/1
4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(
３．ごみの減量方法.PDF
- 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (
07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
untitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
<4D6963726F736F667420576F7264202D2081A193B98BE257656290EA97708CFB8DC08B4B92E88179918D8D878CFB8DC0817A816990568B4B816A81798A6D92E894C5817A2E646F63>
( )
Web Web 1 3 1 21 11 22 23 24 3 2 3 4 5 1 1 11 22 9 2 3 15 11 22 2 11 21 4 5 ( ) 102 ( ) 1 ( 1 2001 Web 1 5 4 1 1 - 7 - [] - 7 10 11 12 12 1 10 1 12 - [] 1 1 2 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 3 1 47
夏目小兵衛直克
39(1906)1222 14(1817) 3(1832)1514(1843) 2628 6 (1853) (1854)3727 3(1856) 1 / 13 5(1858)6(1859) 5(1853) () () () () () () 3(1867)29 504111( 2 / 13 )98 23 18 2(1869)310283 100 50() 58 226 3313200982 5033
nenkin.PDF
1 31 1 WEB 10 3,544 429 13 10 22 11 7 WEB 1 2 41.0 15 80.0 20 46.7% 1000 55.8 1000 34.4 21 18.2 1000 23 25 41.0 49.2 29 90.6 42.7 33 56.4% 79.2% 67.4 51.7 37 39 83.7 1 91.0 93.6 9 2 3 1000 96.3 300 1000
-1-
-1- -2- -3-1 8 6% 2 4 6 8 1 48 63 43 6 55 38 78 58 2 88 67 11 22 78 1 56 22 89 47 34 36 32 38 4 34 26 7 -4- 18-5- 3 25 28 (6.%) (6.%) (.9%) 2 15 18 158 1 (3.8%) (56.4%) 5 2 137 27 8 1 68 119 26 71 28 65
QA Q1. A1. 118 2 Q2. A2. Q3. A3. 1) 2) 3) 4) 5) 6) 7) Q4. A4. 024-536-4343 10:0022:00 03-3264-4343 24 2008/10/15 1 1 2 3 2008/10/15 4: 5() N95 6A() SARS WHO B 7B( 1. 2. (( ) 3. 38 4. 5. 6. 2 2008/10/15
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg
1937 West Nile HA 1957 A/H5 H7 A H1 15 N1 9 A(H1N1) A(H2N2) A(H3N2)
DNA RNA capsid 20 56 30 60 70 30 100 98 98 15 20 2w/v 0.05 0.5w/v 500 5,000ppm 76.9 81.4v/v 70v/v 2.5w/v 0.55w/v 0.3w/v ) ( ) 1937 West Nile 14 39 HA 1957 A/H5 H7 A H1 15 N1 9 A(H1N1) A(H2N2) A(H3N2) 2003
L- 19 L L- L-
0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
137
136 137 16 12 16 17 3 18 138 8 125 144 269 9 125 144 269 10 125 144 269 11 125 144 269 12 125 143 268 13 124 146 270 14 124 147 271 15 124 149 273 16 124 149 273 17 124 152 276 4 1 3 3 3 3 3 3 8 2,641
平成16年警察改革の推進に関する総合評価経過報告書 平成16年8月
14 16 14 10 15 15 -1- 20 12 12 23 11 12 13 12 25-2- -3- -4- 15-5- -6- 14 16 15 11 16 67 16-7- -8- 15 2003 11 WEB 20 550 550 15 288 52.4 152 136-9- -10- 24.7 26.7 13.5 28.2 6.7 53 42 79.2 11 20.8 38 31
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
後期化学_01_濃度
2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml
26 () () (1) (350ml ) (4 ) (2) 10 (3) RC
27 2015 27 2 3 ( 1.0 ) 1. 2. 2015 6 13 ( ) 2015 6 14 ( ) : (URL: http://www.kagakukan.sendai-c.ed.jp) 981 0903 4 1 Tel: 022-276-2201, Fax: 022-276-2204 3. : : : 2015 5 6 ( ) (ID ) 2015 5 11 ( ) () 2015
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
商学５７‐５／１．山村
217 1982 1998 2002 14 7 7 250 3 2 2004 16 2004 a 90 218 1 1 1948 23 25 19 2004 47 3 13 2 14 1969 2 25 25 20 21.1 70 34.5 40 219 50 25 2004 1kg1 l 1,000 mg1 g 250 mg 1mg 1mg 1 mg 19 1911 44 2005 25 50 1498
16
16 ...1...2...3...5...6...6...6...7...8...9...10...10...11...12...12...13...15...15...16...17...18...19...20...21...21...22...23...24...25...25...26...28...30...31...32...33...33...34 ...35...36...37...38...39...40...40...40...40...40...40...40...41...41...41...41...42...42...42...42...43...43...43...44...44...44...44...45...45...45...46...46...46...47...47...48...49...50
rule2018.dvi
30 2018 30 4 21 ( RC ) 1. 2. 2018 6 16 ( ) 2018 6 17 ( ) : (URL: http://www.kagakukan.sendai-c.ed.jp) 981 0903 4 1 Tel: 022-276-2201, Fax: 022-276-2204 3. : : : 2018 5 11 ( ) (ID ) 2018 5 14 ( ) () 2018
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
. R R D e R R 7 () r r R R () l t t R R 7 l () () R r rr r r n r n r r 3 6 r 88 R r 360 r = e t t = e r t rt rt, r t, r 3 t, r t R R R R R D = {e, r,
3 3 3 e X X X X X X . R R D e R R 7 () r r R R () l t t R R 7 l () () R r rr r r n r n r r 3 6 r 88 R r 360 r = e t t = e r t rt rt, r t, r 3 t, r t R R R R R D = {e, r, r, r 3, r, t, rt, r t, r 3 t, r
04-25.S
06-30 MITSUBISHI KAGAKU BIO-CLINICAL LABORATORIES, INC. 18 11 O-06 174-85553-30-1 TEL0359942111 http // www.mbcl.co.jp 12/28() 12/26() 12/28() 12/27() 12/28() 12/28() 12/28() 12/27() 12/26()
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
2 5 28 4 1 47 2
4 4 5 28 1 2 5 28 4 1 47 2 10 10 22 78 10 28 2 2 10% NHK 30% 32% 3 4 5 1 150 1 5 1 20 2 3 1 2008 2 2 2009 2009 3 3 4 DNA 1 3 2 1 3 3 1 5 3 5 8 18 8 30 5 3 2 60 1 5 2 3 60 2 2 2 60 1 1 5 150 6 3 1 2 150
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
−¿Ł¶−w…‹…R-15›¤
794-864 816 838 847 854 864 847 1300 1822 18131822 1828 1862 1912 1936 1813 1828 1822 1862 1822 1813 1862 18131822 1862 1828 851 854 http://www.hi.u-tokyo.ac.jp/ships/shipscontroller ID 00028547 6170.62-2
02
54 163116831 02 1 168 54 158 53 162 53 148 52 152 52 10,000 0 40,000 30,000 20,000 50,000 70,000 60,000 1,000 500 1,500 2,000 0 2,500 3,000 4,000 3,500 4,500 168 54 158 53 162 53 148 52 152 52 03 52148
2 / 7
1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710
学習内容と日常生活との関連性の研究－第１部－第３章
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 366 96 96 66 26 56 57 1 2 58 3 4 5 2004 59 6 70 7 60 9 10 61 366 23 23 15 GPS GPS 62 DNA DNA 63 1 GPS GPS 2004
untitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -